早盘中药（核心股）板块逆势大涨，截至发稿振东制药大涨超19%，生物谷涨超13%，特一药业、汉森 制药涨停，恩威医药（核心股）、大唐药业涨超9%，粤万年青涨超8%，陇神戎发、奇正藏药、上海凯 宝涨超5%。 容，依托中药特色成分打造差异化产品，打开全新增长空间。 同时将梯度培育卓越企业，支持龙头设立产业发展基金、加大上市培育力度，还将推动中药（核心股） 大健康产品创新，打造"中药+"高附加值产业链，全方位促进中药行业规范化、现代化发展。 相关行业： 中药（核心股）材种植加工：方案提出建设高标准中药原料生产基地，鼓励发展中药材现代种业，提升 产地初加工自动化水平，推动制定中药材生产加工质量标准。相关种植加工企业将迎来标准化、规模化 发展机遇，道地药材生产企业将凭借产地属性优势进一步巩固市场地位，实现产品优质优价。 中药（核心股）创新研发：方案鼓励运用人工智能、大数据等技术赋能中药新药研发，推动经典名方、 医疗机构制剂转化为创新药，支持已上市中成药改良升级。布局中药创新研发、循证医学研究的企业将 受益于新药审批和市场推广支持，在创新产品涌现的行业趋势中抢占发展先机。 | | 名称 | 涨幅 | | --- | --- ...

Market Overview - As of January 26, the Shanghai Composite Index fell by 0.09%, closing at 4132.6052 points, while the Shenzhen Component Index decreased by 0.85%, closing at 14316.637 points [1] Top Gainers in Hunan Stocks - Hunan Gold opened at 25.270 and closed at 25.270, with a daily increase of 10.01%, reaching a high of 25.270 and a low of 25.270, with a trading volume of 79,635 lots [2] - Hunan Silver opened at 17.430 and closed at 18.080, with a daily increase of 9.98%, reaching a high of 18.080 and a low of 17.430, with a trading volume of 3,996,619 lots [2] - Tangrenshen opened at 4.300 and closed at 4.510, with a daily increase of 5.13%, reaching a high of 4.510 and a low of 4.250, with a trading volume of 1,047,088 lots [2] - *ST Gauss opened at 12.750 and closed at 12.730, with a daily increase of 4.86%, reaching a high of 12.750 and a low of 12.380, with a trading volume of 141,327 lots [2] - Hansen Pharmaceutical opened at 6.920 and closed at 7.050, with a daily increase of 2.17%, reaching a high of 7.170 and a low of 6.840, with a trading volume of 194,010 lots [2] Top Losers in Hunan Stocks - Hengli Tui opened at 0.160 and closed at 0.150, with a daily decrease of 11.76%, reaching a high of 0.170 and a low of 0.150, with a trading volume of 611,606 lots [3] - Mengjie Shares opened at 4.930 and closed at 4.580, with a daily decrease of 7.10%, reaching a high of 5.030 and a low of 4.530, with a trading volume of 504,009 lots [3] - Yuhuan CNC opened at 24.290 and closed at 22.770, with a daily decrease of 6.14%, reaching a high of 24.380 and a low of 22.600, with a trading volume of 84,859 lots [3] - Shanhe Intelligent opened at 12.750 and closed at 12.120, with a daily decrease of 4.57%, reaching a high of 12.750 and a low of 12.020, with a trading volume of 579,723 lots [3] - Changlan Technology opened at 22.850 and closed at 22.050, with a daily decrease of 4.46%, reaching a high of 22.900 and a low of 21.900, with a trading volume of 152,679 lots [3]

证券日报网讯1月23日，汉森制药（002412）在互动平台回答投资者提问时表示，百贝益肺胶囊的主要 功能为滋阴润肺，止咳化痰。用于治疗肺阴不足咳嗽；慢性支气管炎咳嗽。 ...

证券日报网讯 1月20日，汉森制药在互动平台回答投资者提问时表示，公司可在互动易平台回复非定期 报告时点的月末股东人数，截至2025年12月31日公司的股东人数，公司将在2025年年度报告中披露，后 续可关注公司在指定信息披露媒体及巨潮资讯网披露的相关公告。 （文章来源：证券日报） ...

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.11% on January 12, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index closed at 14366.91, up by 1.75% [1] Stock Performance - Wanbangde (002082) closed at 16.56, with a significant increase of 10.03% and a trading volume of 376,100 shares, amounting to 615 million yuan [1] - Zhenbaodao (603567) rose by 4.62% to close at 9.74, with a trading volume of 185,700 shares [1] - Taiji Group (600129) increased by 2.79% to 19.16, despite a decrease in trading volume of 146,600 shares [1] - Renhe Pharmaceutical (000650) and other companies also showed positive growth, with Renhe closing at 6.18, up by 2.15% [1] Capital Flow - The traditional medicine sector experienced a net outflow of 550 million yuan from institutional investors, while retail investors contributed a net inflow of 460 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde saw a net inflow of 95.22 million yuan from institutional investors, but a net outflow from retail investors of 67.16 million yuan [3] - Other companies like Jianxin Pharmaceutical (002412) and Jilin Aodong (000623) also experienced varying degrees of net inflows and outflows from different investor categories [3]

证券日报网讯1月8日，汉森制药（002412）在互动平台回答投资者提问时表示，公司始终高度重视股东 回报，相关决策严格遵循法律法规及公司章程规定。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a 2.71% increase in stock price on December 19, with a trading volume of 66.22 million yuan, indicating positive market sentiment [1] - On December 19, Hansen Pharmaceutical had a financing buy amount of 7.61 million yuan and a financing repayment of 10.93 million yuan, resulting in a net financing buy of -3.32 million yuan [1] - As of December 19, the total balance of margin trading for Hansen Pharmaceutical was 146 million yuan, which represents 4.25% of its circulating market value, indicating a relatively high level compared to the past year [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include: Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and others, with a total revenue of 741 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 6.75% [2] - The net profit attributable to the parent company for the same period was 82.53 million yuan, showing a year-on-year decrease of 36.88% [2] Group 3 - Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Hansen Pharmaceutical was 24,100, an increase of 0.85% from the previous period [3] - The eighth largest circulating shareholder is Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, holding 2.11 million shares as a new shareholder [3]

Group 1 - The core viewpoint of the article is that Hansen Pharmaceutical (002412) has addressed investor inquiries regarding its research and development status, indicating that detailed information can be found in the company's periodic reports [1] Group 2 - The company encourages investors to refer to its regular reports for comprehensive insights into its R&D activities [1]

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]